Claims
- 1. A nanocrystal linker arm of the following formula:
- 2. The linker arm of claim 1, wherein the attachment point for an organic compound is for an biologically active compound.
- 3. The linker arm of claim 1, wherein the attachment point is for organic compounds selected from the group consisting of: seratonin or seratonin derivatives, cocaine analogues, phenyl tropane analogues, phenylisopropylamine derivatives, dopamine derivatives, melatonin derivatives, chlormethiazole derivatives, derivatives of RTI-4229-75, and derivatives of GBR 12935.
- 4. The linker arm of claim 1, wherein Y is an attachment point for nanocrystals with cross sections less than about 200 angstroms.
- 5. The linker arm of claim 1, wherein Y is an attachment point for nanocrystals selected from the group consisting of CdSe, CdS, PbSe, PbS, and CdTe nanocrystals.
- 6. The linker arm of claim 1, wherein the linker arm is selected from the group consisting of:
- 7. A nanocrystal compound of the following formula:
- 8. The nanocrystal compound of claim 7, wherein the organic compound is selected from the group consisting of: seratonin or seratonin derivatives, cocaine analogues, phenyl tropane analogues, phenylisopropylamine derivatives, dopamine derivatives, melatonin derivatives, chlormethiazole derivatives, derivatives of RTI-4229-75, and derivatives of GBR 12935.
- 9. The nanocrystal compound of claim 7, wherein the organic compound is selected from the group consisting of:
- 10. The nanocrystal compound of claim 7, selected from the group consisting of:
- 11. The compound of claim 7, wherein the nanocrystal has a cross section of less than about 200 angstroms.
- 12. The compound of claim 7, wherein the nanocrystal is selected from the group consisting of CdSe, CdS, PbSe, PbS, and CdTe.
- 13. The compound of claim 7, wherein the organic compound is capable of binding to an affinity molecule, the affinity molecule being a monoclonal antibody, polyclonal antibody, monomeric nucleic acid, oligomeric nucleic acid, protein, polysaccharide, sugar, peptide, drug, ligand.
- 14. The compound of claim 7, wherein the organic compound is seratonin.
- 15. The compound of claim 7, selected from the group consisting of:
- 16. The nanocrystal compound of claim 7, wherein the nanocrystal compound is of the following formula:
- 17. The nanocrystal compound of claim 7, wherein the nanocrystal compound is of the following formula:
- 18. The nanocrystal compound of claim 7, wherein the nanocrystal compound is of the following formula:
- 19. The nanocrystal compound of claim 7, wherein the nanocrystal compound is of the following formula:
- 20. A compound of the following formula:
- 21. A compound of the following formula:
- 22. A compound of the following formula:
- 23. A compound of the following formula:
- 24. A compound of the following formula:
PRIORITY
[0001] This application claims priority under 35 U.S.C. §120 to Application No. 60/206,771, filed May 24, 2000, the contents of which are incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60206771 |
May 2000 |
US |